Advert for Healthcare Professionals Only
I am a patient (Please go to our patient website)
- All Topics
- Allergy and Clinical Immunology
- Anesthesiology
- Angiology
- Cardiology
- Central Nervous System
- Clinical Laboratory
- Complementary and Alternative Medicine
- Critical Care/Intensive Care
- Dermatology
- Diabetes and Endocrinology
- Ear, Nose and Throat
- Emergency Medicine
- Eye Health and Disorders
- Family Medicine
- Gastroenterology
- Gerontology/Geriatrics
- Haematology
- Hepatology
- HIV/AIDS
- Immunology
- Infectious Diseases
- Internal Medicine
- Kidney and Urological Diseases
- Medical Genetics
- Men's Health, Andrology and Urology
- Musculoskeletal Disorders
- Neonatal/Perinatal Medicine
- Neurological Disorders
- Nutrition and Dietetics
- Oncology
- Orthopaedics
- Paediatrics
- Pain Management
- Palliative Medicine
- Plastic Surgery and Aesthetic Medicine
- Podiatry
- Preventive Medicine
- Psychiatry/Mental Health
- Radiology
- Respiratory
- Rheumatology
- Sexual Health
- Sleep Medicine
- Sports Medicine
- Surgery (General)
- Transplantation
- Tropical Medicine
- Vaccines
- Women's Health and Obs/Gyn
- ADHD
- Alzheimer's Disease
- Arthritis
- Atopic Dermatitis
- Cholesterol
- Chronic Myeloid Leukemia
- COPD
- Cystic Fibrosis
- Diabetes
- Gastrointestinal Stromal Tumours
- Hepatitis
- Hypertension
- Insomnia
- Lysosomal Storage Disorders
- Men's Health
- Multiple Sclerosis
- Niemann-Pick type C
- NSCLC
- Opioids and Pain
- Parkinson's Disease
- Post-Myocardial Infarction
- Prostate Cancer
- Renal Anaemia
- Renal Cell Carcinoma
- Soft Tissue Sarcoma
- Third Party Website - Asthma and COPD
- CAPOZIDE TABLETS
- SURMONTIL 10MG AND 25MG TABLETS
- NAPRATEC OP
- COBALIN-H INJECTION
- CARBEX
- CALCIUM RESONIUM 99.934% W/W POWDER FOR ORAL/RECTAL SUSPENSION
- HYPURIN BOVINE ISOPHANE
- HYPURIN BOVINE LENTE
- HYPURIN PORCINE 30/70 MIX CARTRIDGES
- HYPURIN BOVINE ISOPHANE VIALS
- DUKORAL ORAL CHOLERA VACCINE
- OXYNORM LIQUID 5 MG/5 ML ORAL SOLUTION
- DORZOLAMIDE/TIMOLOL EYE DROPS
- FENOFIBRATE 267MG CAPSULES
- TRACRIUM INJECTION
- EXOCIN
- FRAGMIN - TREATMENT OF VTE
- FLUDARABINE PHOSPHATE 50 MG POWDER FOR SOLUTION FOR INJECTION OR INFUSION
- GABITRIL FILM-COATED TABLETS (5 , 10, 15 MG)
- PROTOPIC 0.03% OINTMENT
- XISMOX 60 XL PROLONGED RELEASE TABLETS
- PALLADONE SR CAPSULES
- ZINERYT
- PURI-NETHOL 50 MG TABLETS
- DAKTACORT OINTMENT
- MYLERAN 2 MG FILM-COATED TABLETS
- NEOTIGASON 10MG CAPSULES
- LEUKERAN TABLETS 2 MG
- LANVIS TABLETS 40 MG
- PROVIGIL 100 MG TABLETS, PROVIGIL 200 MG TABLETS
- ADHD
- Alzheimers
- Anxiety Disorders
- Arthritis
- Asthma
- Avonex
- Breast Cancer
- Cervical Cancer
- Cholesterol
- Colorectal Cancer
- Copaxone
- Depression
- Diabetes
- Erectile Dysfunction
- Extavia
- Hypertension
- Insomnia
- Men's Health
- Meningitis
- Migraine
- Pain Management
- Parkinson's
- Pharma News
- Post-MI
- Pregnancy
- Prostate
- Rebif
- Renal anaemia
- Renal Cell Carcinoma
- Thrombosis
- Thromboembolism
- Tysabri
Advert for Healthcare Professionals Only
Latest Drugs
Central Nervous System Drug Data - A-Z (English)
Drug Class Description
Tricyclic antidepressants (TCADs) .Generic Name
AmoxapineDrug Description
50 mg orange tablets; 100 mg blue tablets. Heptagonal, marked LL50 or LL100.Presentation
Tablets, amoxapine 50mg , 100mg .Indications
Depression.Adult Dosage
Initially 100 - 150 mg daily. Usual maintenance, 150 - 250 mg daily; maximum 300 mg daily.Child Dosage
Not recommended.Elderly Dosage
Initially 25 mg twice daily increasing after 5 - 7 days to maximum 50 mg three times daily.Contra Indications
Acute myocardial infarction, heart block, disorders of cardiac rhythm, coronary insufficiency, severe liver disease, mania. Pregnancy and lactation.Special Precautions
Cardiovascular disease, liver disorders, hyperthyroidism, tumours of adrenal medulla, epilepsy, diabetes, glaucoma, urinary retention, constipation, renal disease. Monitor cardiac and hepatic function during long term therapy.
Psychoses, patients with suicidal tendencies. Reduce doses for the elderly.
Interactions
With or within 14 days of MAOIs. Carbamazepine, phenytoin, neuroleptics. Barbiturates, other antidepressants, alcohol, anticholinergics, local anaesthetics containing adrenaline (epinephrine) or noradrenaline (norepinephrine), cimetidine, oestrogens,
Adverse Reactions
Anticholinergic effects such as dry mouth, constipation, urinary retention, blurred vision and changes in accommodation, palpitations and tachycardia. Tinnitus, drowsiness, nervousness or insomnia. Tremor, orthostatic hypotension, dizziness, sweating, weakness and fatigue, ataxia, epileptiform seizures, occasional extrapyramidal symptoms and gastric irritation. Weight loss or gain. Allergic skin reactions, jaundice and blood disorders (test blood regularly).
Conduction defects and cardiac arrhythmias. Endocrine effects such as changes in libido, impotence, gynaecomastia and galactorrhoea. Changes in blood sugar concentrations. Some patients may switch over into mania and schizophrenic symptoms activated, especially in the elderly. Withdrawal symptoms.
Manufacturer
WyethDrug Availability
(POM)Updated
08 June 2009Advert for Healthcare Professionals Only
Related News
TEMSO study for Aubagio in Multiple Sclerosis is published in NEJM Central Nervous System Page
The pivotal Phase III TEMSO study with investigational once-daily oral medication Aubagio (teriflunomide) from Sanofi/Genzyme is published in The New England Journal of Medicine (NEJM). Results showed that teriflunomide at the 14mg dosage significantly reduced the annual relapse rate, reduced disability progressions and improved several magnetic resonance imaging (MRI) measures of disease activity, including new or worsening brain lesions in relapsing, remitting Multiple Sclerosis. Teriflunomide has a well-characterized safety profile, with a similar proportion of trial participants reporting adverse events compared to placebo. Teriflunomide has been filed with the FDA in August of 2011 and the EMA filing is expected in the first quarter of 2012. see Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis Paul O'Connor, M.D., et al for the TEMSO Trial Group N Engl J Med 2011; 365:1293-1303 October 6, 2011.
Tysabri shows benefits in Multiple Sclerosis patients Central Nervous System Page
Patients with Multiple Sclerosis who take anti-inflammatory Tysabri (natalizumab), from Biogen and Elan, for two years showed a reduced risk of experiencing at least one relapse (at 2 years this was reduced by 40%). The study also showed that the number of patients whose disability progressed in the time interval was reduced by 25%. In addition, MRI scans showed evidence that treatment with Tysabri reduced disease activity. Treatment also created some side effects including limb swelling, rigors, vaginal inflammation and menstrual disorders and 2 patients treated with Tysabri for more than 2 years developed Progressive Multifocal Leukoencephalopathy, a rare and often fatal viral disease. In light of this, the researchers recommend further studies. The review was published in The Cochrane Database of Systematic Reviews: "Natalizumab for relapsing remitting multiple sclerosis" by Eugenio Pucci et al. Issue 105 OCT 2011.Tysabri is approved in the USA and EU.
Lemtrada and Aubagio trials to report at ECTRIMS/ACTRIMS congress Central Nervous System Page
Genzyme/Sanofi will report more than 20 abstracts at ECTRIMS/ACTRIMS congress. Data will include Phase III results of Lemtrada(alemutuzumab) and Aubagio ( oral teriflunomide) in relapsing remitting Multiple Sclerosis (MS) including CARE-MS 1 study comparing Lemtrada and Rebif (interferon beta 1-a) in relapsing remitting MS and five year extension of TEMSO study of oral Aubagio (Poster 924) and efficacy of Aubagio (Poster 438) and long term results for Lemtrada CARE-MS Phase II trial (Poster 928) and four year efficacy of Lemtrada in MS (Poster 931). Lemtrada is being developed by Genzyme/Sanofi in the USA and Bayer HealthCare in the EU.
